Intravenous bispecific IgG1 monoclonal antibody (JNJ-61186372) targeting EGFR and MET; blocks ligand binding, induces receptor degradation, and mediates immune effector killing (ADCC and trogocytosis).
Human bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks ligand binding and receptor phosphorylation, induces receptor degradation, and mediates Fc-dependent immune effector killing (ADCC and trogocytosis), thereby inhibiting tumor cell signaling and growth.
Amivantamab binds EGFR on tumor cells and engages Fcγ receptor–bearing immune cells, inducing ADCC and macrophage-mediated trogocytosis; this leads to direct killing of EGFR-expressing cells (in addition to receptor blockade/degradation).
Intravenous bispecific IgG1 monoclonal antibody (JNJ-61186372) targeting EGFR and MET; blocks ligand binding, induces receptor degradation, and mediates immune effector killing (ADCC and trogocytosis).
Human bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks ligand binding and receptor phosphorylation, induces receptor degradation, and mediates Fc-dependent immune effector killing (ADCC and trogocytosis), thereby inhibiting tumor cell signaling and growth.
Amivantamab binds MET on target cells and, via its IgG1 Fc, engages Fcγ receptors on immune effectors (e.g., NK cells/macrophages) to mediate ADCC and trogocytosis/phagocytosis, killing MET-expressing cells.
Small-molecule tyrosine kinase inhibitor targeting ROS1 (also active against NTRK).
Orally bioavailable tyrosine kinase inhibitor that binds the ATP sites of TRK A/B/C (NTRK1/2/3), ROS1, and ALK, blocking kinase phosphorylation and downstream signaling (e.g., MAPK/PI3K pathways), leading to growth inhibition and apoptosis in tumors driven by these fusions/activations.
Entrectinib directly inhibits TRKA kinase activity (ATP-competitive), blocking downstream MAPK/PI3K signaling and inducing growth arrest and apoptosis in TRKA-driven tumor cells.
Small-molecule tyrosine kinase inhibitor targeting ROS1 (also active against NTRK).
Orally bioavailable tyrosine kinase inhibitor that binds the ATP sites of TRK A/B/C (NTRK1/2/3), ROS1, and ALK, blocking kinase phosphorylation and downstream signaling (e.g., MAPK/PI3K pathways), leading to growth inhibition and apoptosis in tumors driven by these fusions/activations.
Entrectinib inhibits TRKB (NTRK2) kinase activity at the ATP-binding site, blocking MAPK/PI3K signaling and inducing growth arrest and apoptosis in TRKB-driven tumor cells.
Small-molecule tyrosine kinase inhibitor targeting ROS1 (also active against NTRK).
Orally bioavailable tyrosine kinase inhibitor that binds the ATP sites of TRK A/B/C (NTRK1/2/3), ROS1, and ALK, blocking kinase phosphorylation and downstream signaling (e.g., MAPK/PI3K pathways), leading to growth inhibition and apoptosis in tumors driven by these fusions/activations.
Entrectinib binds the ATP site of TRKC (NTRK3), inhibits its kinase activity and downstream MAPK/PI3K signaling, leading to growth arrest and apoptosis in TRKC-driven cells.